Can We Afford Medical Advances?

Medical advances, particularly the very expensive new therapeutic agents, will almost certainly not be affordable unless additional mechanisms are developed to deal with their introduction and subsequent use within the NHS. The granting of a product licence should be based on cost-effectiveness as w...

Descripción completa

Detalles Bibliográficos
Autor principal: Williams, Roger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Royal College of Physicians of London 1993
Materias:
Occasional Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396610/
https://www.ncbi.nlm.nih.gov/pubmed/8426347
_version_ 1783230099360841728
author Williams, Roger
author_facet Williams, Roger
author_sort Williams, Roger
collection PubMed
description Medical advances, particularly the very expensive new therapeutic agents, will almost certainly not be affordable unless additional mechanisms are developed to deal with their introduction and subsequent use within the NHS. The granting of a product licence should be based on cost-effectiveness as well as on clinical efficacy and safety as proven by controlled clinical trials. The freedom of individual practitioners to prescribe both in general practice and in hospitals has to be restricted as far as the very expensive drugs are concerned.
format Online
Article
Text
id pubmed-5396610
institution National Center for Biotechnology Information
language English
publishDate 1993
publisher Royal College of Physicians of London
record_format MEDLINE/PubMed
spelling pubmed-53966102019-01-22 Can We Afford Medical Advances? Williams, Roger J R Coll Physicians Lond Occasional Papers Medical advances, particularly the very expensive new therapeutic agents, will almost certainly not be affordable unless additional mechanisms are developed to deal with their introduction and subsequent use within the NHS. The granting of a product licence should be based on cost-effectiveness as well as on clinical efficacy and safety as proven by controlled clinical trials. The freedom of individual practitioners to prescribe both in general practice and in hospitals has to be restricted as far as the very expensive drugs are concerned. Royal College of Physicians of London 1993-01 /pmc/articles/PMC5396610/ /pubmed/8426347 Text en © Journal of the Royal College of Physicians of London 1992 http://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) , which permits non-commercial use and redistribution provided that the original author and source are credited.
spellingShingle Occasional Papers
Williams, Roger
Can We Afford Medical Advances?
title Can We Afford Medical Advances?
title_full Can We Afford Medical Advances?
title_fullStr Can We Afford Medical Advances?
title_full_unstemmed Can We Afford Medical Advances?
title_short Can We Afford Medical Advances?
title_sort can we afford medical advances?
topic Occasional Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396610/
https://www.ncbi.nlm.nih.gov/pubmed/8426347
work_keys_str_mv AT williamsroger canweaffordmedicaladvances

Ejemplares similares